Protara Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · New York, NY
TARA chart
What traders are saying about $TARA
Latest postsProtara Therapeutics, Inc. news
- Protara Therapeutics, Inc. Estimates – NASDAQ:TARA
TradingView ·
- Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Yahoo Finance ·
- Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Yahoo Finance ·
- What Makes Protara Therapeutics (TARA) a New Buy Stock
Yahoo Finance ·
- Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
Yahoo Finance ·
- Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
fool.com ·
- Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Yahoo Finance ·
- Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
Yahoo Finance ·
- Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
Yahoo Finance ·
- Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Yahoo Finance ·
- One Protara Therapeutics Insider Raised Their Stake In The Previous Year
Yahoo Finance ·
Protara Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$57.4M | -$44.6M | -$40.4M | -$66.0M |
| Diluted EPS | $-1.34 | $-2.17 | $-3.57 | $-5.86 |
| Total assets (year end) | $209.5M | $181.5M | $79.0M | $113.3M |
| Cash and equivalents (year end) | $49.7M | $162.8M | $39.6M | $24.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 10-QQUARTERLY REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 10-QQUARTERLY REPORT
- 8-KCURRENT REPORT
- DEF 14APROXY STATEMENT
- 8-KCURRENT REPORT
- 10-KANNUAL REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
About Protara Therapeutics, Inc.
- Ticker
- TARA (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- SEC CIK
- 1359931
- Former names
- Protara Therapeutics, Inc., ArTara Therapeutics, Inc., PROTEON THERAPEUTICS INC
Frequently asked questions
What exchange is Protara Therapeutics, Inc. listed on?
Protara Therapeutics, Inc. trades on the Nasdaq under the ticker symbol TARA.
What industry is Protara Therapeutics, Inc. in?
Protara Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Protara Therapeutics, Inc. headquartered?
Protara Therapeutics, Inc.'s business address on file with the SEC is in New York, NY.
When does Protara Therapeutics, Inc.'s fiscal year end?
Protara Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Protara Therapeutics, Inc. report?
Protara Therapeutics, Inc. reported $2.9M in revenue for calendar year 2014, according to its SEC filings.